These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37248913)

  • 41. Cone-beam computed tomography guided nusinersen administrations in adult spinal muscular atrophy patients with challenging access: a single- center experience.
    Salapura V; Snoj Z; Leonardis L; Koritnik B; Kostadinova V
    Radiol Oncol; 2022 Aug; 56(3):319-325. PubMed ID: 35962954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Administration of nusinersen via paramedian approach for spinal muscular atrophy.
    Iwayama H; Wakao N; Kurahashi H; Kubota N; Hattori A; Kumagai T; Okumura A
    Brain Dev; 2021 Jan; 43(1):121-126. PubMed ID: 32773161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Nusinersen in a late onset spinal muscular atrophy patient for 14 months: A case report.
    Park JM; Min YS; Park D; Park JS
    Medicine (Baltimore); 2021 Jan; 100(1):e24236. PubMed ID: 33429824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy.
    Freigang M; Steinacker P; Wurster CD; Schreiber-Katz O; Osmanovic A; Petri S; Koch JC; Rostásy K; Falkenburger B; Ludolph AC; Otto M; Hermann A; Günther R
    Orphanet J Rare Dis; 2021 Jul; 16(1):330. PubMed ID: 34321067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources.
    Youn B; Proud CM; Wang N; Hou Q; Viscidi E; Eaton S; Paradis AD; Neville BA; Johnson NB
    Adv Ther; 2023 Mar; 40(3):1129-1140. PubMed ID: 36645543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transforaminal intrathecal delivery of nusinersen for older children and adults with spinal muscular atrophy and complex spinal anatomy: an analysis of 200 consecutive injections.
    Weaver JJ; Hallam DK; Chick JFB; Vaidya S; Shin DS; Natarajan N; Rad N; Reis J; Koo KSH; Shivaram GM; Thibodeau A; Apkon S; Monroe EJ
    J Neurointerv Surg; 2021 Jan; 13(1):75-78. PubMed ID: 32471828
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simple Fluoroscopy-Guided Transforaminal Lumbar Puncture: Safety and Effectiveness of a Coaxial Curved-Needle Technique in Patients with Spinal Muscular Atrophy and Complex Spines.
    Jacobson JP; Cristiano BC; Hoss DR
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):183-188. PubMed ID: 31831464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients.
    Müschen LH; Osmanovic A; Binz C; Jendretzky KF; Ranxha G; Bronzlik P; Abu-Fares O; Wiehler F; Möhn N; Hümmert MW; Gingele S; Götz F; Stangel M; Skripuletz T; Schreiber-Katz O; Petri S
    Brain Sci; 2021 Feb; 11(3):. PubMed ID: 33652830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intrathecal delivery of nusinersen in individuals with complicated spines.
    Cartwright MS; Ward ZT; White EP; West TG
    Muscle Nerve; 2020 Jul; 62(1):114-118. PubMed ID: 32319101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
    Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
    Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nusinersen for Patients With Spinal Muscular Atrophy: 1415 Doses via an Interdisciplinary Institutional Approach.
    Madan E; Carrié S; Donado C; Lobo K; Souris M; Laine R; Beers E; Cornelissen L; Darras BT; Koka A; Riley B; Dinakar P; Stone S; Snyder B; Graham RJ; Padua H; Sethna N; Berde C
    Pediatr Neurol; 2022 Jul; 132():33-40. PubMed ID: 35636280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intrathecal Administration of Nusinersen in Pediatric SMA Patients with and without Spine Deformities: Experiences and Challenges over 3 Years in a Single Center.
    Johannsen J; Weiss D; Schlenker F; Groth M; Denecke J
    Neuropediatrics; 2021 Jun; 52(3):179-185. PubMed ID: 33276405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
    Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
    Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nusinersen Administration Via an Intrathecal Port in a 16-Year-Old Spinal Muscular Atrophy Patient with Profound Scoliosis.
    Flotats-Bastardas M; Linsler S; Zemlin M; Meyer S
    Pediatr Neurosurg; 2020; 55(1):54-57. PubMed ID: 31722365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultrasound-guided transforaminal approach for nusinersen delivery in adult spinal muscle atrophy patients with challenging access.
    Snoj Ž; Salapura V
    Muscle Nerve; 2022 May; 65(5):585-589. PubMed ID: 35147227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ultrasound-guided interlaminar approach for nusinersen administration in patients with spinal muscular atrophy with spinal fusion or severe scoliosis.
    Wei C; Liang Z; Wu Y; Liu S; Qiu J; Meng L; Li C; Li S; Bao X; Wang Z; Chen L; Xiong H
    Orphanet J Rare Dis; 2023 Feb; 18(1):30. PubMed ID: 36800969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.